Cencora vs Medline
Cencora is the larger business, with $321.33bn of revenue in fiscal 2025 against $28.43bn for Medline (11.3 times as much). Medline grew faster (11.5% against 9.3%). Medline kept more of each dollar of sales as profit: a net margin of 4.1% against 0.5%.
| Latest fiscal year | CencoraCOR, 2025 | MedlineMDLN, 2025 |
|---|---|---|
| Revenue | $321.33bn | $28.43bn |
| Revenue growth | 9.3% | 11.5% |
| Net income | $1.55bn | $1.15bn |
| Operating margin | — | 7.8% |
| Net margin | 0.5% | 4.1% |
| Return on equity | 144.3% | 10.7% |
| Free cash flow | $3.21bn | $1.30bn |
| Cash | $4.36bn | $1.94bn |
| Total debt | $7.66bn | $12.76bn |
| Debt to equity | — | 118.8% |
| Dividend per share | $2.20 | — |
| Dividend yield | 0.7% | — |
| Share buybacks | $435m | $33.0m |
| Employees | 46,000 | 45,000 |
| Market value | $64.78bn | $27.62bn |
| Price vs our value range | Within our value range | — |
| Moat score | 40 (Weak) | — |
| Insider trades, 12 months | 3 buys, 12 sales | 5 buys, 41 sales |